ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1546

Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry

Sebastian Sattui1, Zihan Wan2, Fenglong Xie2, Cassie Clinton2, Robyn Domsic1 and Jeffrey Curtis3, 1University of Pittsburgh, Pittsburgh, PA, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Hoover, AL

Meeting: ACR Convergence 2022

Keywords: Pharmacoepidemiology, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations suggest discontinuing GC after 1-2 years, prolonged use occurs in a significant proportion of patients. Patients with PMR treated by rheumatology providers are presumably more refractory, and with emerging evidence of recent phase 2/3 studies showing efficacy of steroid-sparring agents, a better understanding of patients with PMR under rheumatologic care and associated treatment patterns are needed. The objective of this study was to describe a national cohort of PMR patients receiving care from rheumatology providers and characterize demographics, disease features, and treatment practices, including the use of steroid-sparing agents.

Methods: Using data from the ACR Rheumatology Informatics System for Effectiveness (RISE) registry from 2016-2020, patients with PMR were identified; requiring age ≥ 50 years and ≥ 2 outpatient diagnostic codes (ICD-9-CM 725/ICD-10 M35.3) separated ≥ 4 weeks apart. Exclusion criteria were other rheumatologic diagnoses including giant cell arteritis and seropositive RA (but not seronegative RA, given potential for clinical overlap). The index date was time of first PMR diagnosis code. Sociodemographic and comorbidity data (using ICD9/ICD10 codes) was collected at the index date. Cumulative comorbidity was measured using the Charlson-Deyo Comorbidity index (CCI). Use of GC and various immunomodulatory antirheumatic medications used as steroid-sparing agents during the first 24 months following the index date was characterized. A similar approach was taken to identifying patients new to rheumatology practices, based on new patient Current Procedural Terminology codes, many of which may have had new onset PMR (i.e., an inception cohort).

Results: A total of 23,125 patients with PMR were included. Patients were predominantly female (61.4%), white (76.6%), with a mean age of 73.5 (SD 9.1) years. The most frequent comorbidities were osteoporosis (17.3%), malignancy (13.2%), and hypertension (12.5%), with the majority of patients having a CCI between 0-1 (88.5%). Prior to the start of follow-up inclusion, methotrexate (8.7%) and hydroxychloroquine (6.4%) were the most frequently used anti-rheumatic medications. At 12-24 months follow-up, most patients remained on GC (61.9%). In the subgroup of 13,896 patients new to rheumatology practices, 90.8% were on GC prior to index date, while only a minority (12.5%) were on an anti-rheumatic medication. At 12-24 months, most patients with continued follow-up remained on GC (65.1%). Although there was an increase in use through follow-up, use of anti-rheumatic medications occurred only in a minority (37.7%) of patients.

Conclusion: We report data on the largest US-based study of PMR patients under rheumatology care using electronic health records data. Use of steroid-sparring agents was low during the first 24 months of follow-up, and the majority of patient remained on GC. Future analyses will focus on describing treatment patterns during follow-up, and identification of factors associated with use steroid-sparring agents for the treatment of PMR.

Supporting image 1

Table 1. Characteristics of patients with Polymyalgia Rheumatica in the RISE registry

Supporting image 2

Table 2. Anti-rheumatic Medications used for Treatment of Polymyalgia Rheumatica During at 12_24 monts of Follow-up

Supporting image 3

Table 3. Therapies Used Over Time in Polymyalgia Rheumatica Patients New to the Rheumatology Practice


Disclosures: S. Sattui, AstraZeneca; Z. Wan, None; F. Xie, Bendcare; C. Clinton, None; R. Domsic, None; J. Curtis, AbbVie/Abbott, Amgen, ArthritisPower, Aqtual, Bendcare, Bristol-Myers Squibb(BMS), CorEvitas, FASTER, GlaxoSmithKlein(GSK), IlluminationHealth, Janssen, Labcorp, Eli Lilly, Myriad, Novartis, Pfizer, Sanofi, Scipher, Setpoint, UCB, United Rheumatology.

To cite this abstract in AMA style:

Sattui S, Wan Z, Xie F, Clinton C, Domsic R, Curtis J. Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/treatment-of-polymyalgia-rheumatica-by-rheumatology-providers-results-from-the-acr-rheumatology-informatics-system-for-effectiveness-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-polymyalgia-rheumatica-by-rheumatology-providers-results-from-the-acr-rheumatology-informatics-system-for-effectiveness-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology